Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Arenberger, Petr ^{[12
]}

Quereux, Gaelle ^{[13
]}

Meniawy, Tarek M. ^{[14
]}

Ascierto, Paolo A. ^{[15
]}

Menzies, Alexander M. ^{[16
]}

Durani, Piyush ^{[17
]}

Lobo, Maurice ^{[17
]}

Campigotto, Federico ^{[17
]}

Gastman, Brian ^{[18
]}

Long, Georgina V. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] Ist Oncol Veneto, IOV IRCCS, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Mar Sklodowska Curie Natl Res Inst Oncol, Gynecol Oncol, Warsaw, Poland

[12] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Cardiol, Prague, Czech Republic

[13] Nantes Univ Hosp, Nantes, France

[14] Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] Ist Nazl Tumori IRCCS Fondaz G Pascale, Naples, Italy

[16] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Cleveland Clin, Cleveland Hts, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 50 条

[31] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (vol 41, pg 1830, 2023)
Herbst
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3877 - 3877
[32] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
Eggermont, A. M. M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.
Marsden, J.
Punt, C. J. A.
Sales, F.
Gore, M.
Mckie, R.
Kusic, V.
Dummer, R.
Musat, E.
Spatz, A.
Keilholz, U.
PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
[33] Subgroup Analysis of the Interim Results of a Prospective, Randomized, Double Blinded, Placebo Controlled, Phase IIb Trial of the Autologous TLPLDC Vaccine in Stage III/ IV ( Resected) Melanoma Patients to Prevent Recurrence
Myers, John W.
Clifton, Guy T.
Vreeland, Timothy J.
Brown, Tommy A.
Peace, Kaitlin
Greene, Julia M.
Jackson, Doreen O.
Hale, Diane F.
Peoples, George E., Jr.
Faries, Mark B.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : S249 - S249
[34] A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results
Ridolfi, L.
Bulgarelli, J.
Piccinini, C.
Carloni, S.
Granato, A.
Petrini, M.
De Rosa, F.
Tazzari, M.
Pancisi, E.
Ancarani, V.
Turci, L.
Gentili, G.
Valmorri, L.
Guidoboni, M.
ANNALS OF ONCOLOGY, 2021, 32 : S1394 - S1394
[35] EORTC 18991:: long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma:: final results of a randomized phase 3 trial
Eggermont, A. M. M.
Suciu, S.
Santinami, M.
Kruit, W.
Testori, A.
Marsden, J.
Punt, C. J. A.
Hauschild, A.
Gore, M.
Keilholz, U.
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2007, 299 (5-6) : 298 - 299
[36] Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
Lucas, Minke W.
Arokoski, Reetta
Menzies, Alexander M.
Pulleman, Saskia
Saw, Robyn P. M.
van Houdt, Winan J.
Faries, Mark B.
Robert, Caroline
Ascierto, Paolo Antonio
Lebbe, Celeste
Carlino, Matteo S.
Kapiteijn, Ellen
Suijkerbuijk, Karijn
Rutkowski, Piotr
Sandhu, Shahneen
Van Der Veldt, Astrid Aplonia Maria
Long, Georgina V.
Blank, Christian U.
van de Poll-franse, Lonneke
Lijnsvelt, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9584 - LBA9584
[37] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Eggermont, Alexander M. M.
Suciu, Stefan
Testori, Alessandro
Santinami, Mario
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Dummer, Reinhard
Robert, Caroline
Schadendorf, Dirk
Patel, Poulam M.
de Schaetzen, Gaetan
Spatz, Alan
Keilholz, Ulrich
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
[38] Clinical outcomes with neoadjuvant nivolumab (N) plus chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial
Spicer, Jonathan
Forde, Patrick M.
Provencio, Mariano
Lu, Shun
Wang, Changli
Mitsudomi, Tetsuya
Broderick, Stephen
Swanson, Scott
Awad, Mark M.
Felip, Enriqueta
Brahmer, Julie R.
Kerr, Keith
Saylors, Gene Brian
Chen, Ke-Neng
Tanaka, Fumihiro
Cai, Junliang
Mahmood, Javed
Hu, Nan
Tran, Phuong
Girard, Nicolas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Witjes, Johannes Alfred
Galsky, Matthew D.
Gschwend, Juergen E.
Broughton, Edward
Braverman, Julia
Nasroulah, Federico
Maira-Arce, Mario
Ye, Xiaomei
Shi, Ling
Guo, Shien
Hamilton, Melissa
Bajorin, Dean F.
EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 553 - 563
[40] Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial (vol 402, pg 798, 2023)
Becker, J. C.
Ugurel, S.
Leiter, U.
LANCET, 2023, 402 (10411): : 1422 - 1422

← 1 2 3 4 5 →